A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
NCT06246968
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Breast Cancer
- Breast Cancer
- Breast Cancer Stage IV
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Metastatic Triple-Negative Breast Carcinoma
- Locally Advanced Breast Cancer
- Locally Advanced Triple-Negative Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- September 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) · Commack, NY
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All protocol activites) · New York, NY
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) · Rockville Centre, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.